Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Creators: name: Fendler, Annika
name: Au, Lewis
name: Shepherd, Scott TC
name: Byrne, Fiona
name: Cerrone, Maddalena
name: Boos, Laura Amanda
name: Rzeniewicz, Karolina
name: Gordon, William
name: Shum, Benjamin
name: Gerard, Camille L
name: Ward, Barry
name: Xie, Wenyi
name: Schmitt, Andreas M
name: Joharatnam-Hogan, Nalinie
name: Cornish, Georgina H
name: Pule, Martin
name: Mekkaoui, Leila
name: Ng, Kevin W
name: Carlyle, Eleanor
name: Edmonds, Kim
name: Del Rosario, Lyra
name: Sarker, Sarah
name: Lingard, Karla
name: Mangwende, Mary
name: Holt, Lucy
name: Ahmod, Hamid
name: Stone, Richard
name: Gomes, Camila
name: Flynn, Helen R
name: Agua-Doce, Ana
name: Hobson, Philip
name: Caidan, Simon
name: Howell, Michael
name: Wu, Mary
name: Goldstone, Robert
name: Crawford, Margaret
name: Cubitt, Laura
name: Patel, Harshil
name: Gavrielides, Mike
name: Nye, Emma
name: Snijders, Ambrosius P
name: MacRae, James I
name: Nicod, Jerome
name: Gronthoud, Firza
name: Shea, Robyn L
name: Messiou, Christina
name: Cunningham, David
name: Chau, Ian
name: Starling, Naureen
name: Turner, Nicholas
name: Welsh, Liam
name: van As, Nicholas
name: Jones, Robin L
name: Droney, Joanne
name: Banerjee, Susana
name: Tatham, Kate C
name: Jhanji, Shaman
name: O’Brien, Mary
name: Curtis, Olivia
name: Harrington, Kevin
name: Bhide, Shreerang
name: Bazin, Jessica
name: Robinson, Anna
name: Stephenson, Clemency
name: Slattery, Tim
name: Khan, Yasir
name: Tippu, Zayd
name: Leslie, Isla
name: Gennatas, Spyridon
name: Okines, Alicia
name: Reid, Alison
name: Young, Kate
name: Furness, Andrew JS
name: Pickering, Lisa
name: Gandhi, Sonia
name: Gamblin, Steve
name: Swanton, Charles
name: Consortium, The Crick COVID-19
name: Nicholson, Emma
name: Kumar, Sacheen
name: Yousaf, Nadia
name: Wilkinson, Katalin A
name: Swerdlow, Anthony
name: Harvey, Ruth
name: Kassiotis, George
name: Larkin, James
name: Wilkinson, Robert J
name: Turajlic, Samra
name: consortium, The CAPTURE
Publisher: name: The Francis Crick Institute
Year: 2022
Subjects: subject: Neurosciences
subject: FOS: Clinical medicine
subject: Model organisms
subject: Biochemistry &amp; Proteomics
subject: Tumour Biology
subject: Signalling &amp; Oncogenes
subject: Genetics &amp; Genomics
subject: Developmental Biology
subject: Genome Integrity &amp; Repair
subject: Human Biology &amp; Physiology
subject: Structural Biology &amp; Biophysics
subject: Cell Biology
subject: Cell Cycle &amp; Chromosomes
subject: Stem Cells
subject: Chemical Biology &amp; High Throughput
subject: Infectious Disease
subject: Ecology,Evolution &amp; Ethology
subject: Immunology
subject: Metabolism
subject: Computational &amp; Systems Biology

description: Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.